48,830
edits
(→Gross) |
|||
Line 7: | Line 7: | ||
| Micro = fatty change (macrovesicular or microvesicular and periportal or centrilobular), negative for ballooning degeneration, negative for significant inflammation - esp. [[neutrophils]] | | Micro = fatty change (macrovesicular or microvesicular and periportal or centrilobular), negative for ballooning degeneration, negative for significant inflammation - esp. [[neutrophils]] | ||
| Subtypes = macrovesicular steatosis (periportal, centrilobular), microvesicular steatosis | | Subtypes = macrovesicular steatosis (periportal, centrilobular), microvesicular steatosis | ||
| LMDDx = [[steatohepatitis]] (ASH, | | LMDDx = [[steatohepatitis]] (ASH, MASH), [[drug-induced liver injury]] | ||
| Stains = | | Stains = | ||
| IHC = | | IHC = | ||
Line 28: | Line 28: | ||
| Prognosis = dependent on underlying cause | | Prognosis = dependent on underlying cause | ||
| Other = | | Other = | ||
| ClinDDx = [[ASH]], [[ | | ClinDDx = [[ASH]], [[MASH]], [[drug-induced liver injury]] | ||
| Tx = dependent on underlying cause | | Tx = dependent on underlying cause | ||
}} | }} | ||
Line 77: | Line 77: | ||
Centrilobular predominant (zone III) - ''DOA'':<ref name=pcddx_steatosis/> | Centrilobular predominant (zone III) - ''DOA'':<ref name=pcddx_steatosis/> | ||
*[[Diabetes mellitus]]. | *[[Diabetes mellitus]]. | ||
*[[Obesity]], | *[[Obesity]], metabolic dysfunction-associated steatohepatitis ([[MASH]]). | ||
*[[Alcoholic liver disease]], alcoholic steatohepatitis (ASH). | *[[Alcoholic liver disease]], alcoholic steatohepatitis (ASH). | ||
edits